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D1 expression, and 5) none of the above. The primary endpoint of this 
study is disease control rate (DCR), which is deﬁned as the fraction 
of patients who are in complete response, partial response, or stable 
disease state 8 weeks after randomization. The primary objective is to 
estimate and to test the DCR for each treatment arm given the patients’ 
biomarker proﬁles. The null DCR and target DCR are set at 0.3 and 
0.6, respectively. A total of 200 patients will be enrolled, stratiﬁed into 
one of the ﬁve marker groups, and then adaptively randomized into one 
of the four treatments. Design parameters were chosen to achieve 20% 
type I error and 90% power. The larger type I error rate was chosen to 
increase the power and to minimize the false negative rate in this phase 
II setting.
We apply the outcome-based adaptive randomization to allocate pa-
tients into treatments based on ongoing and interim observed data. The 
Bayesian ordinal probit model (Albert J and Chib S. Bayesian analysis 
of binary and polychotomous response date, Journal of the American 
Statistical Association, 88, 669-679, 1993) is used to characterize the 
DCR. Gibbs sampling was applied to compute the posterior prob-
abilities. Equal randomization will be performed for the ﬁrst cohort of 
patients, until at least one patient’s treatment outcome is available. Sub-
sequently, the newly enrolled patients will be adaptively randomized 
to one of the four treatment arms according to their biomarker proﬁle. 
The randomization rate is based on the updated posterior DCR from ac-
cumulated data in the trial. For each biomarker proﬁle, better perform-
ing arms will have higher randomization rates and vise versa. Early 
stopping rules are set so that low-performing arms may be suspended 
for new patients being randomized into the arms .
Results: Based on extensive simulation studies, the proposed design 
has the following desirable operating characteristics to: 1) recommend 
effective agents with high probability (80% for DCR=0.5 and 90% 
for DCR= 0.6); 2) recommend ineffective agents with low probability 
(<20% for DCR=0.3; 3) suspend ineffective agents with high probabil-
ity (>60%); and 4) treat more patients with effective agents according 
to their biomarker proﬁles. The Bayesian design incorporates prior 
data and ﬁndings from the current patients to update estimates of the 
treatment efﬁcacy for patients with different biomarker proﬁles. The 
design continues to “learn.” The estimates continue to improve as the 
trial moves forward. The model-based method is useful in combining 
the information gathered from all 20 treatments by marker subgroups to 
make better inference.
Discussion: The Bayesian AR design provides a smart and ethi-
cal design, which is ideally suitable for the development of targeted 
therapy. It can assist in identifying effective agents based on individual 
patients’ tumor biomarker proﬁle, thus providing the ability to treat 
more patients with effective therapies. Compared with the conventional 
approach, the Bayesian design can incorporate data from the literature 
and the interim results from the current trial to form better estimates 
of treatment efﬁcacy for patients in different biomarker proﬁles. It is a 
“smart” design which matches patients with right drugs based on the 
up-to-date information. The information continues to be reﬁned as the 
trial progresses. Important challenges remains to be addressed which 
include the following: 1) Prior speciﬁcations: The choice on how strong 
the prior should be to incorporate the prior information and allow-
ing borrowing strength across treatment and biomarker subgroups; 2) 
Adaptive randomization ratio: Patients with different biomarker proﬁle 
are adaptively randomly assigned to treatments based on the poste-
rior mean of the marginal DCRs. It is an open question on how much 
weight should be given to the posterior DCR; 3) Biased in estimating 
the population DCR. Adaptive randomization can cause bias in estima-
tion due to dependent sampling scheme. It is important to quantify and 
correct the bias; 4) Speciﬁcation on the early stopping rule. Stopping to 
randomize patients into ineffective treatments is desirable but stopping 
too early may result in false negative conclusion; 5) Missing biomarker 
information. In clinical settings, not every patient has a biopsiable 
tumor. In addition, an assessment of the entire biomarker panel may 
not be complete for some patients. Shall patients with no or partial 
biomarker results be enrolled in the study? If so, how? 6) Biomarker 
assessment, outcome evaluation, and accrual. To apply the biomarker 
driven, outcome based adaptive randomization; the time for biomarker 
assessment needs to be short. The time for outcome evaluation needs to 
be relatively short and the accrual cannot be too fast as well, so that the 
decision based on up-to-date data can provide appropriate guidance for 
subsequent patients; 7) Trial conduct. We have developed a database to 
capture the biomarker and outcome information in real time. Bayesian 
computation and the randomization algorithm were written in R. An 
integrated web-base application was built via web services. 
In the midst of many challenges, we have derived an adaptive random-
ization design to achieve our goals of identifying the effective agents 
for patients with different biomarker proﬁles and better treating patients 
on the trial. It is a step towards “personalized medicine.” With the 
growing medical knowledge and molecular/genomic biomarker tools, 
an efﬁcient and ﬂexible design, such as this, will enable us continue to 
learn more about the new agents’ clinical activities and their molecular 
underpinning in real time. Applying this knowledge, we will be able to 
provide better treatments to current and new patients. 
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Motivation: The last decade has seen a veritable explosion in the 
amount of raw information generated by molecular biologists world-
wide. Modern technology today allows the collection of biological 
information at an unprecedented level of detail and in increasingly 
vast quantities. To reap real knowledge from the mountains of data 
produced, however, requires interdisciplinary skills-a background not 
only in biology but also in biostatistics and the bioinformatics tools 
and techniques of data analysis. The motivation of this talk is to help 
the audience meet the challenges of genomic, e.g., microarray experi-
ment, and proteomic, e.g., M(S)ALDI-TOF experiments, research. 
The challenges of these researches include the experiment design, 
data pre-processing, quality control, data mining, pattern recognition, 
class comparison, model prediction, visualization, and interpretation. 
The talk builds the foundation in the biostatistics, bioinformatics, and 
data analysis tools needed by biologists and provides the overview of 
high throughput assays needed by statisticians, mathematicians, and 
bioinformaticians. 
Aims: There are six aims of this talk 
1. Introduction to the high throughput assays - today and tomorrow.
2. Issues of the experiment design of the high throughput assays.
3. Topics of the data pre-processing including the assessment of the 
quality control.
4. Methods of the data analysis: data mining, pattern recognition, class 
comparison, model prediction.
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5. Tools of the visualization
6. How to avoid the common mistakes in analyzing the data derived 
from the high throughput assays.
Targeted audience: Researchers, Molecular Biologist, Clinical Re-
search Scientist, R&D Professionals, IT & Informatics Professionals, 
Statisticians, Bioinformaticians, and mathematicians.
Talk outline: Many of the examples of this talk are based on actual mi-
croarray gene proﬁle data as well as the matrix assisted laser desorption 
ionization time-of-ﬂight, mass spectrometry (MALDI-TOF MS) protein 
proﬁle data that I have analyzed or recently published articles. My hope 
is that the theory of the bioinformatics aspects of the examples would 
provide a springboard for the motivated audience. The topics that will 
be covered in this talk are: 
1. Introduction to the high throughput assays - today and tomorrow.
2. Issues of the experiment design of the high throughput assays.
3. Topics of the data pre-processing including the assessment of the 
quality control.
4. Methods of the data analysis: data mining, pattern recognition, class 
comparison, model prediction.
5. Tools of the visualization
The common mistakes of analyzing the data derived from the high 
throughput assays will be discussed. Several software packages such as 
Wavelet-based Project Spectrum Network (WPSN) package for mass 
spectrum data preprocessing, Weighted Flexible Compound Covariate 
Method (WFCCM) for class prediction, and Mutidimensional Scaling 
and Cluster analysis for visualization will be introduced to the audi-
ence. The goal of this talk is understanding, applying, and not misusing 
the bioinformatics tools in high dimensional data derived from high 
throughput assays.
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Lung cancer is one of the leading causes of death globally. Over the 
past two decades, signiﬁcant advances have been made in the treatment 
of non-small cell lung cancer (NSCLC). Randomized phase III studies 
continue to be the gold standard for deﬁning new standard of care. 
Phase III trials are expensive, time consuming and resource intensive. 
A vast majority (>90%)of phase III trials do not meet their endpoints. 
While the number of new compounds registered for development in 
NSCLC is higher now than ever before, the proportion of adults with 
cancer enrolled in clinical trials is dismally low. There is an urgent need 
to develop novel phase II designs and endpoints that would enable us 
to select compounds /combinations that are likely to succeed in phase 
III trials.
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Pharmacogenomics is known as the science that allows researchers to 
predict the probability of a drug response based on a person’s genetic 
makeup. For instance, it is known that patients with Gilbert’s disease 
associated with UGT1A1 polymorphism will have excessive toxicity 
with the recommended dose of irinotecan due to impaired ability of 
detoxifying the active metabolite of the drug. On the label, “Individu-
als who are homozygous for the UGT1A*28 allele are at increased risk 
for neutropenia following initiation of irinotecan treatment. A reduced 
initial dose should be considered for patients known to be homozygous 
for the UGT1A*28 allele. Heterozygous patients may be at increased 
risk of neutropenia; however clinical results have been variable and 
such patients have been shown to tolerate normal starting doses. 
Although a large amount of new data on relationship between clinical 
outcome of current therapeutic strategies and interindividual genetic 
markers are being published, clinical efﬁcacy and toxicity for the 
individual patient of particular chemotherapy agents are unpredictable 
(Lenz HJ, JCO 2004;22:2519-2521). From the statistical viewpoints, 
we can say that the prediction from UGT1A1 polymorphism to inci-
dence of some toxicity is another issue.
We recently developed a prognostic index to discriminate the risk 
groups among advanced epithelial ovarian cancer based on demo-
graphic, clinical and pathological characteristics of patients (Teramukai 
S, et al. JCO 2007, in press). Accuracy of the simple risk group model 
was statistically evaluated with respect to discrimination and calibra-
tion and reproducibility of the model was accessed by data-splitting 
method. The deﬁnitions of accuracy and generalizability with regard 
to assessment of a prognostic system have been discussed (Justice 
AC, et al. Ann Intern Med 1993;130:515-524). Accuracy (calibration 
and discrimination) is the degree to which predictions match observed 
outcomes. Generalizability (reproducibility and transportability) is the 
ability of a prognostic system to provide accurate predictions in a new 
sample of patients. Reproducibility requires the system to replicate its 
accuracy in patients who were not included in development of the sys-
tem but who are from the same underlying population. Transportability 
requires the system to produce accurate predictions in a sample drawn 
from a different but plausibly related population or in data collected 
by using slightly different methods than those used in the development 
sample. A goal of personalized medicine is to improve such a partially 
validated prognostic system incorporating genomic information, to 
evaluate reproducibility with prospective clinical trials, and to assess 
generalizability with large-scale database on clinical practice.
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Introduction: Our immune system is our body’s natural defense 
mechanism and consists of two types of immune responses, innate vs 
adaptive. Although our immune system is effective in defending against 
infectious diseases, it appears ineffective in defending against a cancer 
once it has been established in the body. Two widely accepted reasons 
that manipulation of the immune system for cancer treatment has been 
unsuccessful are that cancer is not immunogenic and that the cancer 
microenvironment can suppress the immune system. The purpose of 
cancer vaccine or immunotherapy is to elicit a more powerful active 
immunity, either antibody-mediated or cell-mediated, from patients 
to overcome these two barriers to development of therapeutic cancer 
immunity.
